These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37314825)

  • 1. CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    Harris E
    JAMA; 2023 Jul; 330(1):14. PubMed ID: 37314825
    [No Abstract]   [Full Text] [Related]  

  • 2. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    Schulman KA; Greicius MD; Richman B
    JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
    [No Abstract]   [Full Text] [Related]  

  • 4. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA.
    Karlawish J; Grill JD
    Nat Rev Neurol; 2021 Sep; 17(9):523-524. PubMed ID: 34267383
    [No Abstract]   [Full Text] [Related]  

  • 6. CMS Rule Would Increase Cost Transparency of Medicaid-Covered Drugs.
    Harris E
    JAMA; 2023 Jun; 329(24):2118. PubMed ID: 37285174
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.
    Roginiel AC; Dhruva SS; Ross JS
    Medicine (Baltimore); 2018 Oct; 97(40):e12715. PubMed ID: 30290675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
    Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The problematic lag between FDA approval of medical devices and CMS coverage.
    Knight BP; Deering TF; Gold MR; Mittal S; Singh JP
    J Cardiovasc Electrophysiol; 2021 Jul; 32(7):1801-1802. PubMed ID: 34056780
    [No Abstract]   [Full Text] [Related]  

  • 10. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations.
    Wang SS; Smith JJ
    Food Drug Law J; 2003; 58(4):613-27. PubMed ID: 15027453
    [No Abstract]   [Full Text] [Related]  

  • 13. Paying for Cancer Drugs That Prove Their Benefit.
    Frank RG; Emanuel EJ
    JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
    [No Abstract]   [Full Text] [Related]  

  • 14. Will politics sidetrack FDA reform?
    Gatty B
    Formulary; 1995 Aug; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract]   [Full Text] [Related]  

  • 15. Controversy still swirls around FDA user fees: since 1992, the prescription drug user fee act and reauthorizations have sped up new drug approvals--but does speed equal safety?
    Ullman K
    Ann Neurol; 2013 Nov; 74(5):A10-1. PubMed ID: 24353218
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA dependence on drug industry.
    Lawson GW
    J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
    [No Abstract]   [Full Text] [Related]  

  • 17. Retinal implants and Medicare reimbursement policies for breakthrough treatments in ophthalmology.
    Hwang TJ; Ciolino JB
    JAMA Ophthalmol; 2015 Apr; 133(4):373-4. PubMed ID: 25675029
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA and prescription pancreatic enzyme product cost.
    Gardner TB; Munson JC; Morden NE
    Am J Gastroenterol; 2014 May; 109(5):624-5. PubMed ID: 24797000
    [No Abstract]   [Full Text] [Related]  

  • 19. Include Payers in Your Product Development and Clinical Use Processes.
    Schaum KD
    Adv Wound Care (New Rochelle); 2020 Nov; 9(11):632-635. PubMed ID: 32311305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.